Outsourcing BA/BE studies MCQs With Answer is designed to help M. Pharm students master the regulatory, scientific, and operational nuances of outsourcing bioavailability/bioequivalence programs. From selecting and qualifying CROs to understanding global guidelines (FDA, EMA, ICH) and national regulations, this quiz covers end-to-end considerations such as study design, subject safety, data integrity, contracts, bioanalytical validation, and submission readiness. Each question focuses on real-world decision points: vendor oversight, quality agreements, Part 11 compliance, ISR, RSABE, NTI drugs, and more. Use these MCQs to sharpen your regulatory affairs perspective, improve audit/inspection readiness, and gain confidence in planning and supervising outsourced BA/BE studies that are scientifically sound and fully compliant.
Q1. In outsourcing BA/BE studies, what is the most compelling advantage for sponsors seeking quality and speed?
- Eliminating sponsor regulatory responsibility
- Access to specialized expertise and validated infrastructure
- Avoiding ethics committee approval
- Skipping bioanalytical method validation
Correct Answer: Access to specialized expertise and validated infrastructure
Q2. Which guidance clearly states that a sponsor may transfer trial-related duties to a CRO but retains overall responsibility?
- ICH Q7
- ICH E6 (R2) Good Clinical Practice
- OECD GLP Principles
- USP <905>
Correct Answer: ICH E6 (R2) Good Clinical Practice
Q3. In the U.S., which regulation specifically addresses bioavailability and bioequivalence requirements?
- 21 CFR Part 11
- 21 CFR Part 312
- 21 CFR Part 320
- 21 CFR Part 210
Correct Answer: 21 CFR Part 320
Q4. When a CRO uses electronic data capture and LC-MS/MS systems, which regulation ensures compliant electronic records and signatures?
- 21 CFR Part 11
- ICH Q3C
- EMA Module 1
- USP <1225>
Correct Answer: 21 CFR Part 11
Q5. For immediate-release oral formulations, which study design is most commonly used to establish BE?
- Parallel-group single-period design
- Two-period, two-sequence crossover (2×2)
- Factorial design
- N-of-1 trial
Correct Answer: Two-period, two-sequence crossover (2×2)
Q6. For highly variable drugs, which statistical approach may be used to justify widened Cmax limits under certain regulators?
- Population bioequivalence without replication
- Reference-scaled average bioequivalence (RSABE)
- Nonparametric ANOVA
- Super-bioavailability testing
Correct Answer: Reference-scaled average bioequivalence (RSABE)
Q7. Which PK metrics are typically used to decide bioequivalence for most immediate-release products?
- Ctrough and AUCtau with 95% CI within 70.00–143.00%
- Cmax and AUC with 90% CI within 80.00–125.00%
- Tmax only with nonparametric test
- Kel and t½ with 90% CI within 90.00–110.00%
Correct Answer: Cmax and AUC with 90% CI within 80.00–125.00%
Q8. Which contract document best defines scope, deliverables, timelines, and responsibilities for an outsourced BA/BE project?
- Master Service Agreement (MSA)
- Quality Agreement
- Statement of Work (SOW)
- Change Control Form
Correct Answer: Statement of Work (SOW)
Q9. What is the primary purpose of a pre-award site qualification audit of a CRO/clinical unit for BA/BE?
- To negotiate the lowest per-subject cost
- To evaluate compliance systems, capabilities, and capacity
- To finalize the clinical trial insurance certificate
- To confirm the marketing authorization holder
Correct Answer: To evaluate compliance systems, capabilities, and capacity
Q10. Which activity verifies the reproducibility of bioanalytical results using actual study samples?
- Calibration curve evaluation
- Dilution integrity
- Incurred Sample Reanalysis (ISR)
- Carryover assessment
Correct Answer: Incurred Sample Reanalysis (ISR)
Q11. For most drugs, what is the standard regulatory acceptance interval for the 90% CI of Test/Reference geometric mean ratios?
- 75.00–133.00%
- 80.00–125.00%
- 70.00–143.00%
- 90.00–110.00%
Correct Answer: 80.00–125.00%
Q12. For narrow therapeutic index (NTI) drugs in BE studies, which statement is generally true?
- Wider acceptance limits are usually allowed
- Tighter acceptance limits and additional metrics may be required
- Only Tmax needs to be matched
- Parallel design is mandatory
Correct Answer: Tighter acceptance limits and additional metrics may be required
Q13. In India, the conduct and approval of BA/BE studies are currently governed primarily by which rules?
- Schedule M of Drugs and Cosmetics Rules
- Schedule Y (superseded framework)
- New Drugs and Clinical Trials Rules, 2019 (NDCTR 2019)
- Medical Devices Rules, 2017
Correct Answer: New Drugs and Clinical Trials Rules, 2019 (NDCTR 2019)
Q14. Before sharing a protocol and proprietary data with a potential CRO, which agreement is typically executed?
- Purchase Order
- Confidentiality/Non-Disclosure Agreement (CDA/NDA)
- Financial Disclosure Form
- Insurance Binder
Correct Answer: Confidentiality/Non-Disclosure Agreement (CDA/NDA)
Q15. Which approach best supports sponsor oversight of an outsourced BA/BE study?
- Delegating all monitoring to the CRO with no sponsor review
- A documented vendor oversight plan with KPIs and governance meetings
- Auditing only after database lock
- Relying solely on CRO marketing materials
Correct Answer: A documented vendor oversight plan with KPIs and governance meetings
Q16. In a 2×2 crossover BE study, which factor most strongly drives sample size requirements?
- Inter-subject variability only
- Intra-subject variability (CV%) of key PK parameters
- Number of analytical batches
- Washout duration
Correct Answer: Intra-subject variability (CV%) of key PK parameters
Q17. Regarding informed consent in BA/BE studies, which is correct?
- The sponsor obtains consent after dosing
- The investigator obtains consent only before randomization
- The investigator must obtain consent before any study-specific procedures
- The CRO project manager documents consent on behalf of the investigator
Correct Answer: The investigator must obtain consent before any study-specific procedures
Q18. If a bioanalytical run fails predefined acceptance criteria, what is the appropriate action?
- Report results as is and note a deviation
- Exclude failing QCs and keep the rest
- Investigate, document root cause, and repeat the run per SOP and acceptance criteria
- Adjust calibration curve post hoc to force acceptance
Correct Answer: Investigate, document root cause, and repeat the run per SOP and acceptance criteria
Q19. In data integrity, ALCOA refers to which set of principles?
- Available, Logical, Consistent, Objective, Auditable
- Attributable, Legible, Contemporaneous, Original, Accurate
- Assured, Legal, Controlled, Organized, Archived
- Accessible, Licensed, Certified, Operational, Authorized
Correct Answer: Attributable, Legible, Contemporaneous, Original, Accurate
Q20. For FDA submissions, which forms disclose clinical investigator financial interests in BA/BE studies?
- Form FDA 1572
- Form FDA 356h
- Forms FDA 3454/3455
- FDA 483
Correct Answer: Forms FDA 3454/3455
